ORCID Profile
0000-0002-8516-0040
Current Organisation
University of Veterinary Medicine Vienna
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 23-04-2013
DOI: 10.1111/VCP.12039
Abstract: A chronic loss of canine α1 -proteinase inhibitor (cα1 -PI) into the gastrointestinal (GI) tract could change the systemic proteinase-proteinase inhibitor balance. Serum cα1 -PI concentrations have not been studied in dogs with well-defined GI diseases. To further evaluate serum cα1 -PI concentrations in dogs with GI diseases, the objectives of this study were to (1) analytically validate a previously developed fecal cα1 -PI immunoassay to determine serum concentrations, (2) determine a population-based reference interval (RI) and assess the clinical utility, (3) determine stability of serum cα1 -PI, (4) determine the intra-in idual variation in healthy dogs, and (5) determine the clinically relevant magnitude of change of serum cα1 -PI. Prestudy validation of the (125) I-cα1 -PI immunoassay included linearity, spiking recovery, and intra- and inter-assay precision. A RI was calculated with s les of healthy dogs. Stability at -20°C was tested on 36 s les. Intra-in idual variation was assessed using s les collected from 11 healthy dogs over a 12-week period. The cα1 -PI radioimmunoassay (RIA) was linear, accurate, precise, and reproducible. Serum cα1 -PI decreased by 11% after one year at -20°C. Analytical, intra-in idual, inter-in idual, and total variation were 6.4, 9.9, 9.0, and 25.3%, respectively. The RI for serum cα1 -PI was 732-1802 mg/L (n = 87) there were no differences between sex and age groups. The index of in iduality was 1.31. As analytical variation was > ½ inter-in idual variation, the minimum critical difference was not determined. The results of this study provide the basis for further evaluating serum cα1 -PI in dogs with GI disease. Using a population-based RI for serum cα1 -PI appears to be appropriate.
Publisher: American Veterinary Medical Association (AVMA)
Date: 10-2008
Abstract: Objective —To determine whether lymphocyte apoptosis in intestinal mucosae is more common in healthy dogs than dogs with inflammatory bowel disease (IBD) and whether numbers of apoptotic cells increase after successful treatment of affected dogs. Animals —8 dogs with IBD (IBD dogs) and 8 healthy control dogs. Procedures —Biopsy specimens of the duodenum and colon were obtained via endoscopy from dogs with IBD before and after 10 weeks of standard treatment and compared with specimens obtained from control dogs. Expression of activated caspase 3 (Casp3), caspase-cleaved fragment p85 from poly-ADP-ribose polymerase (PARP), and B-cell leukemia/lymphoma 2 (Bcl-2) was measured in the duodenal (villous tip and base) and colonic mucosae. Results —Expression of Casp3 was greater in the duodenal villous tips of control dogs, compared with expression in similar tissues from dogs with IBD before or after treatment. Despite clinical improvement of dogs with IBD, expression of Casp3 did not increase after treatment. Expression of PARP did not differ between groups at any time point. Expression of Bcl-2 was greater at all 3 tissue sites in control dogs, compared with expression at the same sites in dogs with IBD. Furthermore, Bcl-2 expression in duodenal villous tips was higher in dogs with IBD after treatment but was not higher elsewhere. In control dogs, expression patterns for all 3 markers were similar between sites (villous tip villous base colon). Conclusions and Clinical Relevance —Expression of Casp3 in lymphocytes in duodenal villous tips was significantly reduced in dogs with IBD, compared with expression in healthy dogs, but no increase was detected following successful treatment of IBD. Increased expression of Bcl-2 may be a potential marker of the success of treatment.
Publisher: MDPI AG
Date: 19-10-2021
Abstract: Alimentary lymphomas arising from T cells are rare and aggressive malignancies in humans. In comparison, they represent the most common anatomical form of lymphoma in cats. Due to the low prevalence in humans, the underlying pathomechanism for these diseases is poorly characterised, limiting experimental analysis and therapeutic exploration. To date, activating mutations of the JAK/STAT core cancer pathway and particularly the STAT5B oncoprotein have been identified in human enteropathy-associated T cell lymphoma. Here, we describe a high homology of human and feline STAT3 and STAT5B proteins and strong conservation at the genomic level. Analysis of 42 s les of feline T cell alimentary lymphoma reveals broad activation of STAT3 and STAT5B. Screening for known activating mutations in STAT3 or STAT5B identifies the presence of the STAT5BN642H driver mutation in feline enteropathy-associated T cell lymphoma in 7 out of 42 (16.67%) s les in total. Regarding lymphoma subtypes, the majority of mutations with 5 out of 17 (29.41%) cases were found in feline enteropathy-associated lymphoma type II (EATL II). This identification of an oncogenic STAT5B driver mutation in felines recapitulates the genetic situation in the corresponding human disease, thereby establishing the cat as a potential new model for a rare and incurable human T cell disease.
No related grants have been discovered for Iwan Anton Burgener.